Presentation TCT 2016

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Presenter: John A. Spertus

October 30, 2016

REGISTER for free or LOG IN to view this content

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Presentation

TCT 2016

Quality

Up Next

Presentation TCT 2016

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Presenter: Pascal Vranckx

October 30, 2016

More slides +

Presentation TCT 2016

Should Clinical Trial Interpretation Be Dominated by A P Value of 0.05 for the Primary Endpoint?

Presenter: Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Levels of Evidence: Single-center vs Multicenter Trials

Presenter: Roxana Mehran

October 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.